drugset / Trial / NCT01836549
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Phase 2
Terminated
43 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-03
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imetelstat | Oligonucleotide (other) | 285 mg/m2 | Intravenous |